Novai develops early detection and intervention methods for eye and brain diseases using proprietary DARC technology. This platform provides clinicians with faster data for appropriate treatment selection and supports pharmaceutical companies in ophthalmic drug development. The technology aims to prevent severe vision loss and disability through advanced diagnostic capabilities.
Funding
$6.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting retinal biomarkers associated with glaucoma and age-related macular degeneration (AMD) often lack the sensitivity needed for early diagnosis. Delayed detection can lead to irreversible vision loss and reduced treatment effectiveness.
Solution
Novai utilizes DARC (Detection of Apoptosing Retinal Cells) technology to enable earlier and more precise detection of retinal biomarkers linked to glaucoma and AMD. This technology aims to improve the efficiency of clinical trials by providing more sensitive endpoints and accelerate the selection of appropriate treatments for eye and brain diseases. By facilitating earlier intervention, Novai's approach seeks to reduce the risk of blindness and disability associated with these conditions. The company's services cater to patients, clinicians, and pharmaceutical companies, offering benefits across the spectrum of eye care.
Target Audience
Novai serves ophthalmologists and optometrists seeking advanced diagnostic tools, pharmaceutical companies conducting ophthalmic drug trials, and patients at risk of or affected by glaucoma and AMD.
Features
- DARC technology for early detection of apoptosing retinal cells.
- Enhanced sensitivity in identifying retinal biomarkers.
- Improved clinical trial efficiency through more precise endpoints.
- Accelerated treatment selection timelines.